US Patent

US7531623 — Hydrochloride salts of a glycopeptide phosphonate derivative

Composition of Matter · Assigned to Theravance Inc · Expires 2027-01-01 · 1y remaining

Vulnerability score 27/100 Strong — defensible against typical IPR challenges

What this patent protects

This patent protects hydrochloride salts of telavancin with a specific chloride ion content, which have improved stability during storage at ambient temperatures.

USPTO Abstract

Disclosed are hydrochloride salts of telavancin having a chloride ion content of from about 2.4 wt. % to about 4.8 wt. %. The disclosed salts have improved stability during storage at ambient temperatures compared to other hydrochloride salts. Also disclosed are processes for preparing such salts.

Drugs covered by this patent

Patent Metadata

Patent number
US7531623
Jurisdiction
US
Classification
Composition of Matter
Expires
2027-01-01
Drug substance claim
Yes
Drug product claim
No
Assignee
Theravance Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.